Indra 9M26 slides: backlog soars 133% on IRIS² space contract

Indra’s nine-month 2026 revenue rose 28.6% to €4,645 million and EBITDA increased 62% to €657 million, while backlog surged 133% to €22.2 billion, driven in part by €1.9 billion of IRIS² orders in Q3. Reported free cash flow was €1,692 million, including €1,809 million in net prepayments from Spain’s Special Modernisation Programs; comparable free cash flow excluding specified prepayments and factoring effects was €70 million. Indra reaffirmed 2026 guidance of €7.0 billion in revenue, €700 million in EBIT and more than €375 million in free cash flow excluding PEM prepayments.

Analysis

The key quality-of-earnings issue is that the cash and backlog optics are stronger than the near-term earnings signal. PEM advances improve liquidity today but reverse as Indra funds delivery; the reported net-cash position therefore overstates recurring balance-sheet strength. Before assigning value to it, reconcile reported and comparable free cash flow and track cash conversion excluding advances. IRIS² backlog is also a long-dated execution obligation, not equivalent to near-term revenue: subcontracting, milestone timing and the stated €500–540m capex burden determine its eventual return. Space’s margin jump should be treated cautiously given the consolidation mix and the unusually large contract base.

Near term, a strong order book can support sentiment, but the shares’ proximity to their annual high makes a chase unattractive. Over 1–3 months, the test is whether Q4 deliveries sustain guidance while Defence margins normalize as indicated and comparable cash flow remains positive. Over 6–18 months, the upside case depends on converting defence and satellite awards into production without cost overruns; Minsait’s weak demand and Mobility’s investment-phase margins are offsets. Concentration in Spanish public programs adds budget, payment-timing and execution risk. The contrarian point: record backlog may already be treated as durable growth, while its long duration and advance-funded working capital make earnings and cash conversion—not order intake—the better leading indicators.

Key Decisions for Investors

• Do not chase the post-results move. Consider a staged long in Indra only on weakness or after confirmation that full-year guidance is met; use comparable free cash flow and delivery progress, not reported net cash, as the entry thesis.
• For a 1–3 month catalyst, monitor Q4 Defence deliveries and margin normalization, plus cash flow excluding PEM advances and factoring. Reassess the long thesis if guidance is cut, comparable cash flow turns materially negative, or program costs rise without matching delivery milestones.
• Avoid valuing IRIS² backlog as immediate earnings. Track capex, subcontractor economics and milestone awards; a delay or weaker-than-expected contribution to operating profit would undermine the Space-led re-rating.
• Relative-value watch: compare Indra’s execution and valuation with European defence peers such as Thales and Leonardo before taking a sector pair. The supplied data do not establish relative valuation or consensus expectations, so there is not yet a sufficiently grounded short leg.